Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Phenazopyridine · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Phenazopyridine Hydrochloride Tablets, USP 200 mg | ACTIVE_COMPARATOR | - |
| Placebo | PLACEBO_COMPARATOR | Matching placebo to the phenazopyridine hydrochloride tablets |
| Name | Type | Description |
|---|---|---|
| Phenazopyridine Hydrochloride | DRUG | Tablets, 200 mg, every 8 hours for 48 hours. |
| Placebo | DRUG | Tablets, every 8 hours for 48 hours |
Inclusion Criteria: * Diagnosis of uncomplicated urinary tract infection (uUTI) * Must have one of the following uUTI diagnosis * Cystitis * Urethritis * A Positive urine dipstick test showing nitrate or leukocyte esterase (LE) * Negative pregnancy test (if applicable) * Must have one or both of th...
Phenazopyridine is used for pain associated with urinary tract infections. It is a small molecule being developed by Amneal Pharmaceuticals, Inc. (AMRX) and is currently in Phase 3 clinical development as an investigational drug.
Phenazopyridine is a small molecule that targets pain associated with urinary tract infections. It is being studied for its ability to relieve pain in this condition, though the specific molecular target is not detailed.
Phenazopyridine is being developed by Amneal Pharmaceuticals, Inc., which trades under the ticker AMRX. The company is conducting clinical trials to evaluate the drug's safety and efficacy for pain related to urinary tract infections.
Phenazopyridine is in Phase 3 clinical development. It is an investigational drug and has not been approved by the FDA. A Phase 3 trial has been completed to assess its safety and efficacy.
Phenazopyridine has one completed Phase 3 trial, NCT01064024, which evaluated the safety and efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg versus placebo. The trial enrolled 233 female participants aged 18 years and older in the United States.
Phenazopyridine is the same as Phenazopyridine Hydrochloride, as indicated by the clinical trial title. The drug is being studied in tablet form at a 200 mg dose for pain associated with urinary tract infections.